Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Richard A Chudleigh,1 Julia Platts,2 Stephen C Bain1,3 1Singleton Hospital, Swansea Bay University Health Board, Swansea, UK; 2Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK; 3Diabetes Research Unit Cymru, Swansea University Medical School, Swan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chudleigh RA, Platts J, Bain SC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	type 2 diabetes glp-1 receptor agonists long-acting glp-1ras Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a62ddcdd92ec4bee901c150944eab50a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a62ddcdd92ec4bee901c150944eab50a
record_format	dspace
spelling	oai:doaj.org-article:a62ddcdd92ec4bee901c150944eab50a2021-12-02T09:16:20ZComparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data1178-7007https://doaj.org/article/a62ddcdd92ec4bee901c150944eab50a2020-02-01T00:00:00Zhttps://www.dovepress.com/comparative-effectiveness-of-long-acting-glp-1-receptor-agonists-in-ty-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Richard A Chudleigh,1 Julia Platts,2 Stephen C Bain1,3 1Singleton Hospital, Swansea Bay University Health Board, Swansea, UK; 2Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK; 3Diabetes Research Unit Cymru, Swansea University Medical School, Swansea, UKCorrespondence: Richard A Chudleigh Email Richard.Chudleigh3@wales.nhs.ukAbstract: Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW “long-acting” GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.Keywords: GLP-1, type 2 diabetes, cardiovascular trialChudleigh RAPlatts JBain SCDove Medical Pressarticletype 2 diabetesglp-1 receptor agonistslong-acting glp-1rasSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 433-438 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes glp-1 receptor agonists long-acting glp-1ras Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes glp-1 receptor agonists long-acting glp-1ras Specialties of internal medicine RC581-951 Chudleigh RA Platts J Bain SC Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
description	Richard A Chudleigh,1 Julia Platts,2 Stephen C Bain1,3 1Singleton Hospital, Swansea Bay University Health Board, Swansea, UK; 2Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK; 3Diabetes Research Unit Cymru, Swansea University Medical School, Swansea, UKCorrespondence: Richard A Chudleigh Email Richard.Chudleigh3@wales.nhs.ukAbstract: Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW “long-acting” GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.Keywords: GLP-1, type 2 diabetes, cardiovascular trial
format	article
author	Chudleigh RA Platts J Bain SC
author_facet	Chudleigh RA Platts J Bain SC
author_sort	Chudleigh RA
title	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_short	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_full	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_fullStr	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_full_unstemmed	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_sort	comparative effectiveness of long-acting glp-1 receptor agonists in type 2 diabetes: a short review on the emerging data
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a62ddcdd92ec4bee901c150944eab50a
work_keys_str_mv	AT chudleighra comparativeeffectivenessoflongactingglp1receptoragonistsintype2diabetesashortreviewontheemergingdata AT plattsj comparativeeffectivenessoflongactingglp1receptoragonistsintype2diabetesashortreviewontheemergingdata AT bainsc comparativeeffectivenessoflongactingglp1receptoragonistsintype2diabetesashortreviewontheemergingdata
_version_	1718398202458144768

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Ejemplares similares